How should we best target the biology of ER PR HER2 negative breast cancer?

被引：0
|
作者：
Tutt, A. N. J. [1 ]
Reis-Filho, J. S. [2 ]
机构：
[1] Kings Coll London, Breakthrough Breast Canc Res Unit, London WC2R 2LS, England
[2] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(08)70703-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：166 / 166
页数：1
相关论文
共 50 条
  • [21] Breast cancer ER, PR, and HER2 expression variance by germline cancer predisposition genes.
    Wei, Grace
    Rosa, Marilin
    Chang, Maxine
    Czerniecki, Brian J.
    Wang, Xia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] Case report: From negative to positive: a remarkable journey of ER, PR and HER2 status in a patient with metastatic breast cancer
    Huang, Jiaqi
    Liu, Lan
    Ding, Jianghua
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [23] Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer
    Perez, Edith A.
    Patel, Tejal
    Moreno-Aspitia, Alvaro
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 121 (02) : 261 - 271
  • [24] Analysis of 47 Patients with Triple Negative (ER, PGR, HER2) Breast Cancer
    Gunes, Mehmet Emin
    Celik, Gurhan
    Trabulus, Fadime Didem
    Aksoy, Sefika
    Ozoran, Emre
    Aren, Acar
    Gucin, Zuhal
    Bahadir, Fadime
    ISTANBUL MEDICAL JOURNAL, 2012, 13 (04): : 166 - 168
  • [25] Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer
    Edith A. Perez
    Tejal Patel
    Alvaro Moreno-Aspitia
    Breast Cancer Research and Treatment, 2010, 121 : 261 - 271
  • [26] HER2 low and ER low breast cancer
    Schnitt, Stuart
    JOURNAL OF PATHOLOGY, 2023, 261 (SUPPL1): : S7 - S7
  • [27] ER, PR, Her2, and Ki-67 Expression in Male and Female Breast Cancer
    Lockyer, M. G.
    Martinez-Blanco, E.
    Verstovsek, G.
    Bedrosian, I.
    Albarracin, C.
    Rosen, D.
    LABORATORY INVESTIGATION, 2013, 93 : 54A - 55A
  • [28] Indicator measures ER/PR and HER2 testing among women with invasive breast cancer
    Sandoval, C.
    Rahal, R.
    Forte, T.
    Klein-Geltink, J.
    He, D.
    Bryant, H.
    CURRENT ONCOLOGY, 2013, 20 (01) : 62 - 63
  • [29] ER, PR, Her2, and Ki-67 Expression in Male and Female Breast Cancer
    Lockyer, M. G.
    Martinez-Blanco, E.
    Verstovsek, G.
    Bedrosian, I.
    Albarracin, C.
    Rosen, D.
    MODERN PATHOLOGY, 2013, 26 : 54A - 55A
  • [30] Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer
    Yang, Yu-Feng
    Liao, Ying-Yang
    Li, Le-Qun
    Xie, Shu-Rui
    Xie, Yan-Fang
    Peng, Ning-Fu
    PATHOLOGY RESEARCH AND PRACTICE, 2013, 209 (12) : 797 - 802
12345